Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Gastrocnemius Plane Block vs IV Analgesia for Foot and Ankle Surgery
NCT05463809Phase 3Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 3, randomised, single-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Area under the pain intensity-time curve at 48 hours. Status: unknown.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05463809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463809.